Jacques Galipeau | Immunology and Microbiology | Research Excellence Award

Published on by Forensic Scientist

Dr. Jacques Galipeau | Immunology and Microbiology | Research Excellence Award

University of Wisconsin-Madison | United States

Dr. Jacques Galipeau is a leading translational immunologist recognized for seminal contributions to mesenchymal stromal cell (MSC) biology, immune modulation, and engineered cytokine therapeutics. His research has reshaped global understanding of MSC immunogenicity, functional potency, and clinical limitations, directly influencing regulatory science and advanced cell therapy development. He pioneered the discovery and translation of fusokines, a novel class of synthetic cytokines with applications in autoimmunity, cancer immunotherapy, transplantation tolerance, and regenerative medicine. His work bridges mechanistic immunology and first-in-human translation, with sustained impact across academia and clinical development. According to Google Scholar, Dr. Jacques Galipeau has authored 478 peer-reviewed publications, received 23244 citations, and holds an h-index exceeding 71, reflecting sustained global influence.

                        Citation Metrics (Google Scholar)

30000

25000

20000

15000

10000

5000

0

 

Citations
23444
Documents
478
h-index
71

Citations

Documents

h-index

View Google Scholar Profile

Featured Publications


Mesenchymal stromal cells: clinical challenges and therapeutic opportunities

– J. Galipeau, L. Sensébé · Cell Stem Cell, 2018 · Cited by 1868


Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages

– J.S. Wang, D. Shum-Tim, J. Galipeau et al. · J Thorac Cardiovasc Surg, 2000 · Cited by 976


Mesenchymal stem versus stromal cells: ISCT® position statement on nomenclature

– S. Viswanathan, Y. Shi, J. Galipeau et al. · Cytotherapy, 2019 · Cited by 866

Human MSC suppression correlates with cytokine-induced IDO and M2 macrophage differentiation

– M. François, R. Romieu-Mourez, M. Li, J. Galipeau · Molecular Therapy, 2012 · Cited by 862

Allogeneic marrow stromal cells are immune-rejected by MHC-mismatched recipients

– N. Eliopoulos, J. Stagg, L. Lejeune et al. · Blood, 2005 · Cited by 700

Ying Cui | Immunology and Microbiology | Excellence in Research Award

Published on by Forensic Scientist

Ms. Ying Cui | Immunology and Microbiology | Excellence in Research Award

Beijing Friendship Hospital, Capital Medical University | China

Ms. Ying Cui is an emerging neuroscientist whose research advances the understanding of the gut–brain axis, neurodegeneration mechanisms, and biomarker innovation in Parkinson’s disease (PD). Her work integrates metagenomics, multi-parameter clinical imaging, molecular neuroscience, and machine-learning analytics to improve diagnostic precision and support translational therapeutic development. With 6 Scopus-indexed publications, 85 citations, and an h-index of 2, her research impact continues to grow across both clinical and experimental domains. Ms. Ying Cui has contributed to high-value research projects, including multicenter clinical trials and national-level neuroscience studies, where she played key roles in microbiome profiling, experimental methodology, and advanced neuroimaging assessment using ¹²³I-MIBG scintigraphy. Her first-author publications provide novel insights into the diagnostic performance of cardiac and extra-cardiac washout rate parameters for differentiating PD from Parkinson-plus syndromes, offering clinically relevant imaging markers for complex diagnostic scenarios. Complementing her imaging research, Ying has developed a high-accuracy metagenomic diagnostic model with 99% validation accuracy and identified functional probiotic strains with the potential to modulate α-synuclein aggregation, mitochondrial dysfunction, and neuroinflammatory signaling work that has led to a PCT international patent for a probiotic composition targeting REM Sleep Behavior Disorder. Her multidisciplinary contributions span biomarker discovery, clinical–computational integration, translational microbiome innovation, and cross-institutional collaborations in neurology, microbiology, metabolomics, and bioinformatics. Through this synergistic research portfolio, Ying Cui continues to advance early diagnostic strategies, mechanistic insights, and therapeutic innovation in Parkinson’s disease, establishing herself as a rising researcher in translational neurodegeneration science.

Profiles: Scopus | ORCID

Featured Publications

  • Xue, T., Cui, Y., Kan, Y., & Yang, J. (2025). Value of extra-cardiac sympathetic nervous uptake parameters based on ¹²³I-MIBG SPECT/CT in the assessment of Parkinson’s disease. Clinical and Translational Imaging.

  • Xue, T., Cui, Y., Kan, Y., & Yang, J. (2025). Value of multi-parameter ¹²³I-MIBG scintigraphy in the differential diagnosis of Parkinson’s disease. EJNMMI Research.

Yuyan Tang | Immunology and Microbiology | Best Researcher Award

Published on by Forensic Scientist

Prof. Yuyan Tang | Immunology and Microbiology | Best Researcher Award

Minhang Hospital, Fudan University | China

Prof. Yuyan Tang is a clinician-scientist specializing in nephrology and molecular immunopathology, with a strong research focus on the gut–kidney axis, IgA nephropathy, and chronic kidney disease (CKD). Her studies elucidate the mechanisms by which intestinal microbiota, short-chain fatty acids (SCFAs), and NLRP3 inflammasome signaling influence renal inflammation and fibrosis, integrating molecular biology with traditional Chinese medicine interventions. She has led several competitive research projects funded by the National Natural Science Foundation of China and regional scientific bodies, advancing translational insights into renal disease mechanisms and microbiome-based therapeutic strategies. Prof. Yuyan Tang has published 23 peer-reviewed documents indexed in Scopus, garnering 287 citations across 262 citing documents, with an h-index of 8. Her scientific contributions include 8 first- or corresponding-author SCI papers with a total impact factor of 52.7, notably featuring a highly cited article in Circulation Research and impactful publications in Nephrology Dialysis Transplantation and BMC Microbiology. Recognized as a Youth Talent Awardee at Fudan University’s Affiliated Minhang Hospital, Prof. Yuyan Tang’s research continues to bridge microbiome regulation and nephrology through innovative molecular and clinical investigations.

Profile: Scopus

Featured Publications

  • Tang, Y., Zhu, Y., He, H., Sun, W., Wu, J., Xiao, Y., … Xu, X. (2024). IgA nephropathy: Gut microbiome regulates the production of hypoglycosylated IgA1 via the TLR4 signaling pathway. Nephrology Dialysis Transplantation, 39(10), 1624–1641.

  • Jiang, L., He, H., Tang, Y., Li, J., Reilly, S., Xin, H., … Cai, H. (2024). Activation of BK channels prevents diabetes-induced osteopenia by regulating mitochondrial Ca2+ and SLC25A5/ANT2-PINK1-PRKN-mediated mitophagy. Autophagy, 20(11), 2388–2404.

  • Li, H., Xu, M., Xu, X., Tang, Y., Jiang, H., Li, L., … Yang, T. (2022). Faecalibacterium prausnitzii attenuates CKD via Butyrate-Renal GPR43 Axis. Circulation Research, 131(9), e120–e134.

  • Tang, Y., Xiao, Y., He, H., Zhu, Y., Sun, W., Hu, P., … Xu, X. (2023). Aberrant gut microbiome contributes to barrier dysfunction, inflammation and local immune responses in IgA nephropathy. Kidney and Blood Pressure Research, 48(1), 261–276.

  • Tang, Y., Zhu, Y., He, H., Peng, Y., Hu, P., Wu, J., … Xu, X. (2022). Gut dysbiosis and intestinal barrier dysfunction promote IgA nephropathy by increasing the production of Gd-IgA1. Frontiers in Medicine, 9, 944027.

Monika Prylińska-Jaśkowiak | Immunology and Microbiology | Young Scientist Award

Published on by Forensic Scientist

Mrs. Monika Prylińska-Jaśkowiak | Immunology and Microbiology | Young Scientist Award

Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University | Poland

Mrs. Monika Prylińska-Jaśkowiak is an emerging clinician-scientist whose professional journey reflects a rare balance between medical practice, academic excellence, and translational research. She earned her Doctor of Medical Sciences degree from Collegium Medicum, Nicolaus Copernicus University in Toruń, where her doctoral research focused on the relationship between the gut microbiome and chronic fatigue syndrome, integrating clinical insight with advanced molecular and bioinformatic analyses. As a specialist pediatrician at the Voivodeship Children’s Hospital in Bydgoszcz, she combines her research background with everyday patient care and is currently pursuing specialization in pediatric rheumatology. Her scientific contributions include peer-reviewed publications such as The gut microbial composition is different in chronic fatigue syndrome than in healthy controls (Scientific Reports, 2025), and review papers in the Journal of Education, Health and Sport (2022), widely cited for summarizing current knowledge on CFS/ME and human gut microbiota. Mrs. Monika Prylińska-Jaśkowiak’s research interests encompass pediatric immunology, microbiome–immune interactions, and chronic inflammatory diseases, with a focus on precision diagnostics and targeted therapy development. Actively engaged in professional societies including the Polish Pediatric Society and the Polish Society of Vaccinology, she continues to expand her expertise through certified courses in resuscitation, vaccinology, and emergency pediatrics. Her commitment to continuous learning, clinical excellence, and evidence-based innovation exemplifies the spirit of a modern physician-scientist dedicated to improving child health and advancing medical science.

Profile: ORCID | LinkedIn

Featured Publications

• Prylińska, M., & Kożuchowski, M. (2022, September 28). The human gastrointestinal tract microbiota in health – current knowledge summary. Journal of Education, Health and Sport, 12(10). https://doi.org/10.12775/JEHS.2022.12.10.005

• Kożuchowski, M., & Prylińska, M. (2022, April 30). The proper functioning of the sense of smell and its disturbances on the example of COVID-19 infection. Journal of Education, Health and Sport, 12(4). https://doi.org/10.12775/JEHS.2022.12.04.026

Majid Taati Moghadam | Immunology and Microbiology | Best Researcher Award

Published on by Forensic Scientist

Assist. Prof. Dr. Majid Taati Moghadam | Immunology and Microbiology | Best Researcher Award

Guilan University of Medical Sciences | Iran

Dr. Majid Taati Moghadam is a dedicated Medical Microbiologist and Antimicrobial Resistance Researcher based in Rasht, Iran. He specializes in microbial pathogenesis, antibiotic resistance mechanisms, bacteriophage therapy, and the connection between microbiota and neurodegenerative disorders. His multidisciplinary expertise extends across clinical microbiology, infectious disease prevention, and translational therapeutics, making him a leading figure in Iran’s microbiological research community.

Professional Profile

Scopus

Google Scholar

ORCID

Education

Dr. Majid Taati holds a Ph.D. in Medical Bacteriology from Iran University of Medical Sciences (2017–2022), where his research investigated the relationship between oral microbiome shifts and Alzheimer’s disease. He earned his Master’s degree in Medical Microbiology from Kerman University of Medical Sciences (2012–2015), focusing on carbapenem resistance genes in Klebsiella pneumoniae. His academic journey began with a Bachelor’s degree in Microbiology from Islamic Azad University, Lahijan Branch (2007–2012). Throughout his studies, he demonstrated a keen interest in antibiotic resistance, clinical diagnostics, and the molecular biology of pathogens.

Experience

Dr. Majid Taati has played key roles in over a dozen microbiological research projects across Iran. As both a principal investigator and main collaborator, he has contributed to studies on extended-spectrum beta-lactamase (ESBL) genes, resistance enzymes in E. coli, and the antimicrobial effects of plant extracts like Ephedra pachyclada. He has worked extensively on projects involving nosocomial infections, multidrug-resistant bacteria, and genetic analysis methods such as MLVA and HRM techniques. He also authored the textbook Essential Medical Microbiology in Persian, and presented his findings at several major Iranian congresses, including the International Microbiology Congress. His laboratory and academic experience bridges both applied research and educational leadership.

Research Interests

Dr. Majid Taati research focuses on antimicrobial resistance mechanisms, phage and endolysin therapy, bacterial biofilm inhibition, and engineered phage enzymes for resistant infections. He is also deeply involved in exploring the role of microbiota in neurological and neuropsychiatric disorders, especially Alzheimer’s disease. His studies aim to bridge clinical microbiology with therapeutic innovation addressing global health threats posed by superbugs like carbapenem- and colistin-resistant Gram-negative bacteria. His recent projects extend to wound healing biomaterials, phage protein therapies, and microbiome-based diagnostics, reflecting his broad and multidisciplinary scientific interests.

Awards

Recognized for his extensive research contributions, Dr. Majid Taati is a deserving nominee for the “Best Researcher Award” in medical microbiology and antimicrobial resistance. His scholarly excellence, particularly in phage therapy and resistance gene profiling, aligns well with the objectives of scientific bodies that honor groundbreaking research. With dozens of publications in top-tier journals and continuous involvement in nationally significant projects, he exemplifies leadership in translational microbiology and global infectious disease research.

Publications

  • Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis
    Year: 2020
    Citations: 316

  • Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review
    Year: 2020
    Citations: 311

  • How phages overcome the challenges of drug resistant bacteria in clinical infections
    Year: 2020
    Citations: 173

  • Bacteriophages, a new therapeutic solution for inhibiting multidrug-resistant bacteria causing wound infection: lesson from animal models and clinical trials
    Year: 2020
    Citations: 125

  • COVID-19 (Coronavirus disease 2019): a new coronavirus disease
    Year: 2020
    Citations: 108

  • Evaluation of Nano-curcumin effects on expression levels of virulence genes and biofilm production of multidrug-resistant Pseudomonas aeruginosa isolated from clinical samples
    Year: 2019
    Citations: 108

  • Bacteriophage as a novel therapeutic weapon for killing colistin-resistant multi-drug-resistant and extensively drug-resistant gram-negative bacteria
    Year: 2021
    Citations: 58

Conclusion

Dr. Majid Taati Moghaddam Ziabari has built an impressive career defined by scientific innovation, deep academic rigor, and a commitment to combating infectious diseases. His pioneering work in bacteriophage therapy and antimicrobial resistance not only advances microbiological science but also addresses some of the most urgent global health challenges. With his rich publication record, research leadership, and academic influence, he is a prime candidate for international recognition, especially the Best Researcher Award. His career serves as a model of excellence in translational research and academic impact.